Under the guise of patient education.

AIDS Healthcare Basis blasts GlaxoSmithKline print advertisements that promote fear of HIV treatment AIDS Healthcare Base is blasting British multi-national medication giant GlaxoSmithKline for a recently available series of direct-to-consumer print advertisements that, under the guise of patient education, capitalize on individuals’ fears of HIV treatment. In a July 30th letter to Mike Leavitt, Secretary of the U.S. Department of Health and Human Services , AHF President Michael Weinstein mentioned: ‘The attached print ad may be the most egregious exemplory case of this kind of advertising. This ad is designed to instill dread in the thoughts of AIDS individuals by informing them that switching AIDS treatment can lead to improved side-results and potentially treatment failure., a specialty pharmaceutical firm focused on the advancement and commercialization of innovative therapies for the treating acute and breakthrough pain, today announced that ARX-04 met main and secondary endpoints in a multi-middle, double-blind, placebo-controlled Phase 3 trial made to research the short-term treatment of patients with moderate-to-severe acute agony following ambulatory abdominal medical procedures.001). Adverse occasions reported in the analysis were common of opioid therapy and were similar for patients treated with ARX-04 and placebo, the most typical which were nausea, vomiting and headache.